RxDoctor Payments Data

Andre Leonard, MD

Internal Medicine · Wilmington, NCNPI 1720019193

Payments from drug & device makers

$2,887in general payments, 2019–2025

Across 203 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$373
  • AstraZeneca$292
  • Lilly USA, LLC$216
  • Pfizer$185
  • GSK$166
  • Amgen$156
  • plus $1K from 37 others

What the payments were for

  • Food & beverage$2,879100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,887 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$369,117
Medicare patients
807
Services billed
8,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor12$481,478
OzempicSemaglutide174$183,596
MounjaroTirzepatide92$129,649
EliquisApixaban92$88,555
JardianceEmpagliflozin71$83,140
XareltoRivaroxaban86$77,106
Repatha SureclickEvolocumab104$75,845
TrulicityDulaglutide45$67,051
FarxigaDapagliflozin Propanediol60$54,462
JanuviaSitagliptin Phosphate29$34,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$28,507
MyrbetriqMirabegron37$25,991
Synjardy XrEmpagliflozin/Metformin Hcl26$24,473
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$24,379
Repatha SyringeEvolocumab27$23,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda$55$481,47812 claims
Lilly USA, LLCMounjaro, Trulicity, Zyprexa$216$213,206149 claims
Novo NordiskOzempic, Wegovy$373$202,542188 claims
Boehringer IngelheimJardiance, Synjardy Xr$108$107,61297 claims
PfizerEliquis, Nurtec Odt$185$103,352105 claims
Johnson & JohnsonXarelto$59$77,10686 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$166$71,55496 claims
AstraZenecaFarxiga$292$54,46260 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Ambien$63$30,95237 claims
Astellas Pharma US IncMyrbetriq$38$25,99137 claims
AbbVieLinzess, Synthroid$137$23,553149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →